glp-1 obesity drug study august 2025 Alarming rise in weight loss overdoses Unpacking $100B+ Obesity Market Opportunity:

Novo Nordisks semaglutide-based treatments, Wegovy and Ozempic, have established a strong market presence

Coverage is shifting rapidly

Methods This analysis did not require ethical approval, and a protocol was not pre-registered

The combination targets the brain reward pathways involved in food cravings, particularly emotional and hedonic eating

The 2019 Global Consensus Position Statement on testosterone use in women established that testosterone therapy is associated with improvements in lean mass, bone density, and sexual function in postmenopausal women [24]

Amycretin (Novo Nordisk's GLP-1/amylin dual agonist) has shown up to 22% weight loss in Phase 1